This Article  • Full text  • PDF  • Correction  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on Web of Science (4)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in JAMA  Social Bookmarking   What's this?

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: The Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) provides further evidence on the benefit of statin treatment for primary prevention of coronary heart disease (CHD).¹ The relative risk (RR) reduction for nonfatal myocardial infarction (MI) and CHD death (42%) was broadly similar to that in previous statin trials. However, the population studied had a much lower risk of CHD than those enrolled in previous studies, with a rate of nonfatal MI and CHD death in the placebo group of 0.6% per year. As a result, the absolute risk reduction for these events was much smaller than in previous trials, at around 0.2% per year. This corresponds to a number needed to treat (NNT) of 86 to prevent 1 CHD event over 5 years.

There is now broad agreement that lipid-lowering treatment should be targeted at a specified level of absolute CHD risk^2-4 because this risk determines absolute . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLES

Increased Cancer Mortality Following a History of Nonmelanoma Skin Cancer
Henry S. Kahn, Lilith M. Tatham, Alpa V. Patel, Michael J. Thun, and Clark W. Heath, Jr
JAMA. 1998;280(10):910-912.
ABSTRACT | FULL TEXT  

Antiatherothrombotic Properties of Statins: Implications for Cardiovascular Event Reduction
Robert S. Rosenson and Christine C. Tangney
JAMA. 1998;279(20):1643-1650.
ABSTRACT | FULL TEXT